See below - our basher is the lowest of the low- like arguing with an 8 year old who doesn't want to go to bed at midnight "cause I'm not tired"- well for this basher the clock has struck 12.
BAX Q3 CC 2013
David R. Lewis - Morgan Stanley, Research Division
Just maybe a few quick questions here. Ludwig, just first on HyQ filing, it's in the script, but it wasn't specific. Can you just give us an update on where we stand on HyQ filing at the end of the year here? And have you received any additional questions from the agency post BioPharma's decision to end their hyaluronidase program?
Ludwig N. Hantson - Corporate Vice President and President of Bioscience
So we're still on schedule to submit our file before the end of the year, David. We've not gotten any additional questions from the FDA. We expect that the regulatory path forward is well defined, and we expect a potential 6-months review. So that means that we are getting ready for a potential launch of HyQ in the U.S. second half of next year.
maybe analysts were paying attention and we will start seeing upgrades ? probably not, they will wait until we're trading at $20 and then they will raise their estimates to $25 - $30. makes sense...why pay $12 now when you can pay $23 in 6 months?
Analyst just asked for more info about filing. Baxter added that FDA has asked no additional questions and that assuming approval, HyQvia launch will be in H2 2014. They later added that they continue reimbursement in one European country for HyQvia, and will also continue to "nail down reimbursement" in several other European countries this year.
Sentiment: Strong Buy
That was then and this is now with 2 euro approvals + 1 pending and significant US clinical progress on several fronts beyond HyQ and - I think it came after the US filing for HyQ - PFE partnership for six products. Should be worth more than double that 13.50, though I doubt that it will be awarded that price. Not even with Chile tossed in.